Search clinical trials for: Pramipexole ER

Total 847 results

Boehringer Ingelheim

Completed

Bioavailability of Increasing Pramipexole Doses of Oral Extended Release (ER) Tablets in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Increasing Dose Study of Pramipexole in Two-way Cross-over Comparison of ER Tablet Versus IR Tablet in Japanese Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Terminated

Pramipexole ER vs. Placebo in Fibromyalgia

Fibromyalgia

United States
Boehringer Ingelheim

Completed

Pivotal Study in Advanced Parkinsons Disease Patients

Parkinson Disease

Austria, Czech Republic, Hungary, India, Italy, Korea, Republic of, Philippines, Poland, Russian Federation, Slovakia, Spain, Sweden, Ukraine, United Kingdom
Boehringer Ingelheim

Completed

Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients

Early Parkinson Disease (Early PD)

United States, Argentina, Austria, Czech Republic, Finland, Germany, Hungary, India, Japan, Malaysia, Russian Federation, Slovakia, Taiwan, Ukraine
Boehringer Ingelheim

Completed

Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers

Healthy
Pharma Two B Ltd.

Completed

A Phase 3 Study With P2B001 in Subjects With Early Parkinson's

Parkinson Disease | Early Parkinson's Disease

United States, Canada, Germany, Spain
Boehringer Ingelheim

Completed

In Vitro/in Vivo Correlation (IVIVC) for Oral Slow Release (SR) Tablets Pramipexole in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Influence of Pramipexole on the QT Interval of the ECG in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Terminated

Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome

Tourette Syndrome

United States, Germany
Seoul National University Hospital

Unknown

Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID)

Parkinson's Disease

Korea, Republic of
Boehringer Ingelheim

Completed

Multiple Dose Bioequivalence Study of Pramipexole Extended Release in Chinese Healthy Male Volunteers

Healthy

China
Boehringer Ingelheim

Completed

A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period

Parkinson Disease

Japan
Boehringer Ingelheim

Completed

A Randomised, Comparing Fixed Doses of Pramipexole to Investigate the Efficacy and Safety in Patients With RLS.

Idiopathic Restless Legs Syndrome

Japan
Boehringer Ingelheim

Completed

The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa

Parkinson Disease

China
Dexa Medica Group

Completed

Bioequivalence Study of Two Formulations of Pramipexole Tablets 0.25 mg

Healthy

Indonesia
First Affiliated Hospital of Zhejiang University
Hongguan biological pharmaceutical co.

Terminated

Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets (PLKS-BE)

Parkinson's Disease

China
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Withdrawn

To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS

Multiple Sclerosis | Sperm

United States
Boehringer Ingelheim

Completed

Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome

Restless Legs Syndrome

Japan
Rhode Island Hospital

Completed

Improving Emotion Regulation Skills Among Adolescents Attempting to Lose Weight

Overweight and Obesity

United States
Columbia University
Biolase Inc

Active, not recruiting

Peri-implantitis Treatment: Clinical Results of Conventional Treatment vs. the Addition of Biolase

Peri-Implantitis

United States
HealthPartners Institute

Terminated

Outreach-ER: A Dementia Care Intervention Program

Dementia

United States
TaiRx, Inc.

Completed

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients

Advanced Cancer

Taiwan
Boehringer Ingelheim

Completed

Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease

Parkinson Disease

France, Germany, Netherlands
Uppsala University

Recruiting

Emotion Regulation Training for Adolescents With ADHD

ADHD | Emotion Regulation | Attention Deficit Disorder With Hyperactivity

Sweden
Jewish General Hospital

Recruiting

Emergency Room Visits and Older Patients (ER2) (ER2)

Emergencies | Length of Stay

Canada
Medical University of South Carolina
Georgia State University

Completed

PTSD Treatment and Emotion Regulation Skills Training for Veterans With Military Sexual Trauma (PE+ER) (PE+ER)

Anxiety Disorders | Stress Disorders, Post-Traumatic | Mental Disorder | Traumatic Stress Disorder

United States
Asieris Pharmaceuticals (AUS) Pty Ltd.

Completed

A Phase I, Two-phase, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APL-1501 ER Tablets

Bladder Cancer

Australia
Member Companies of the Opioid PMR Consortium

Terminated

Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain

Opioid-Related Disorders | Drug Abuse | Opiate Addiction | Narcotic Abuse

United States
Washington State University
American Society for Pain Management Nursing

Recruiting

Empowered Relief Delivered by Nurses (ERA)

Pain, Chronic

United States
National Institute of Mental Health (NIMH)

Completed

Assessment of [11C]ER176 to Image Translocator Protein in Brain and Whole Body of Healthy People

Pharmacokinetics | Adult

United States
Boehringer Ingelheim

Completed

Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients

Parkinson Disease

China
Boehringer Ingelheim

Completed

Long-term Administration Study of SND 919 Tablets in Parkinson's Disease

Parkinson Disease
Korea University Anam Hospital

Completed

YSGG Application in Periodontal Treatment

Periodontal Diseases

Korea, Republic of
Lotus Pharmaceutical

Completed

Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine

Migraine Without Aura | Migraine With Aura

Taiwan
Sandoz

Completed

Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease

Parkinson's Disease

Korea, Republic of
Kowa Research Institute, Inc.

Completed

Study to Investigate the Efficacy and Pharmacokinetic Profile of K-877-ER Compared to K-877-IR

Dyslipidemia

United States
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
Ultragenyx Pharmaceutical Inc

Completed

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy (HIBM)

United States
Boehringer Ingelheim

Completed

Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)

Parkinson Disease

United States, Austria, Finland, France, Germany, Italy, Japan, Spain, Sweden, United Kingdom
Boehringer Ingelheim

Completed

Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances

Depression | Restless Legs Syndrome

Finland, France, Germany, Ireland, Italy, Korea, Republic of, Spain, Sweden, United Kingdom
Augusta University
GlaxoSmithKline

Completed

SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole

Restless Legs Syndrome

United States
Lars Adolfsson

Recruiting

Non-operative Treatment in Sweden of Proximal Humeral Fractures (NOSWEPH)

Proximal Humeral Fracture

Sweden
University Hospital Inselspital, Berne

Completed

Feasibility of REBOA in Refractory Cardiac Arrest

Heart Arrest

Switzerland
University of British Columbia
Children's & Women's Health Centre of British Columbia

Terminated

Sup-ER Protocol RCT

Birth Related Brachial Plexus Injury | Obstetrical Brachial Plexus Palsy

Canada
Boehringer Ingelheim

Completed

Bioavailability of Four Oral Prototype Extended Release Formulations With BI 11634 in Healthy Male Volunteers

Healthy
Impax Laboratories, LLC

Completed

Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease

Idiopathic Parkinson's Disease

United States
Boehringer Ingelheim

Completed

a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients

Parkinson Disease

China
Boehringer Ingelheim

Completed

Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients

Restless Legs Syndrome

Germany, Austria, Netherlands, Norway, Sweden
Oregon Health and Science University
Boehringer Ingelheim

Completed

Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease (DALI)

Parkinson's Disease

United States

Search clinical trials for: Pramipexole ER

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations